# Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Kidney Cancer

> **NCT03540199** · PHASE2 · WITHDRAWN · sponsor: **Fuda Cancer Hospital, Guangzhou**

## Conditions studied

- Advanced Kidney Cancer

## Interventions

- **BIOLOGICAL:** Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Kidney Cancer
- **PROCEDURE:** cryotherapy

## Key facts

- **NCT ID:** NCT03540199
- **Lead sponsor:** Fuda Cancer Hospital, Guangzhou
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-04-10
- **Primary completion:** 2020-05-20
- **Final completion:** 2020-09-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No participant enrolled
- **Last updated:** 2020-10-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03540199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03540199, "Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Kidney Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03540199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*